BAY-1082439
As of the edition of 20 October 2026, BAY-1082439 is a small molecule: went quiet in 2017; acts on PIK3CA and PIK3CB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 1 company-target row on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of BAY-1082439.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company-target row is on route A because of BAY-1082439.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bayer | Lead sponsor of trials | 2012 to now |